Prognosis and predictive value of KIT exon 11 deletion in GISTs.
J-B Bachet , I Hostein , A Le Cesne , S Brahimi
British Journal of Cancer 101 ( 1) 7 -11
34
2009
FOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases (RCSM): Final results of the FFCD 1102 phase II trial
J-B Bachet , O Lucidarme , CB Levache , E Maillard
Annals of Oncology 28 v171 -v171
2017
Tumeurs digestives : côlon — rectum
J-B Bachet , J Taïeb , E Mitry , P Rougier
Springer Paris 359 -386
2011
Should Liver Metastasis of Pancreatic Ductal Adenocarcinoma Be Resected?
M Muzzolini , R Lupinacci , J-B Bachet , A Sauvanet
HPB 25 S473 -S474
2023
% TTD and% TUDD: New SAS macro programs to calculate the survival data of the time to deterioration for patient-reported outcomes data in oncology
Emilie Charton , A Falcoz , E François , Célia Touraine
Computer Methods and Programs in Biomedicine 214 106537 -106537
2022
Focus on hENT1 and other biomarkers
J-B Bachet
Oncologie 17 528 -534
2015
Development and validation of AI-assisted transcriptomic signatures to personalize adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma
N Fraunhoffer , P Hammel , T Conroy , R Nicolle
Annals of Oncology
Performances of preoperative CT scan to predict the pTN stage for MSI/dMMR localized colon cancers
M Duval , Q Vanderbecq , V Phou , B Cervantes
ESMO open 9 ( 8) 103678 -103678
2024
Development and validation of AI-assisted transcriptomic signatures to personalize adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma
N Fraunhoffer , P Hammel , T Conroy , R Nicolle
Annals of Oncology
2024
DLL4 expression is a prognostic marker and may predict gemcitabine benefit in resected pancreatic cancer
A Drouillard , F Puleo , J B Bachet , S Ouazzani
British Journal of Cancer 115 ( 10) 1245 -1252
8
2016
Récepteurs tyrosine-kinase, voies de signalisation et tumeurs digestives
Jean-Baptiste Bachet
Versailles-St Quentin en Yvelines
2013
Cancer colique asymptomatique avec métastases hépatiques synchrones non résécables : faut-il réséquer le primitif ?
Laurent Hannoun , Mehdi Karoui , Jean-Baptiste Bachet , Jean-Christophe Vaillant
Hépato-Gastro & Oncologie Digestive 20 ( 6) 424 -430
2013
KRAS mutations in colorectal cancer is a predictive factor of response and progression free survival in patients treated with Cetuximab.
Valerie Boige , Jean-Francois Cote , Philippe Rougier , Gorana Tomasic
Cancer Research 67 5671 -5671
9
2007
[Colorectal cancer: what progress can we anticipate in the next few years?].
Jean-Baptiste Bachet , Philippe Rougier
La Revue du praticien 60 ( 8) 1111
1
2010
Colon and rectal tumours
Gilles Lesur , Jean-Baptiste Bachet , Philippe Rougier
La Revue du praticien 59 ( 3) 383 -391
2009
Prise en charge des perforations coliques endoscopiques iatrogènes : le point de vue de l’endoscopiste
Yann Le Baleur , Frédérick Moryoussef , Mehdi Karoui , Jean-Baptiste Bachet
Hépato-Gastro & Oncologie Digestive 23 ( 5) 392 -401
2016
Molecular aspects and perspectives in pancreatic cancer: evolutions and revolutions?
Jean-Baptiste Bachet , Cindy Neuzillet
Hépato-Gastro & Oncologie Digestive 24 ( 2) 61 -69
2017
Adénocarcinome du pancréas métastatique : prise en charge en 2020
Jean-Baptiste Bachet , Léo Mas
Hépato-Gastro & Oncologie Digestive 27 ( 6) 585 -595
2020
Oncology (excluding colorectal cancer and hepato-carcinoma)
Jean-Baptiste Bachet
Hépato-Gastro & Oncologie Digestive 27 ( 8) 819 -823
2020
Role of FOLFIRINOX and chemoradiotherapy in locally advanced and borderline resectable pancreatic adenocarcinoma: update of the AGEO cohort.
Nicolas Williet , Angélique Vienot , Jean-Baptiste Bachet , Eric Francois
British Journal of Cancer 1 -8
2021